Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

We explore the history of global pharmaceutical group Hoffmann-La Roche from where it first began, to its core structure and its focus for the future in personalised medicine. Roche was found in ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

You can now play an even larger range of puzzles on our site, every weekday and now also every Saturday. Check out our brand new puzzles below, from Hangman to Add Up and even a Jigsaw. Of course ...

To determine the prevalence of the mutations in the thrombophilia panel, the subjects were genotyped for FV G1691A, FII G20210A, PAI 4G/5G, and FXIII V35L variants using real-time polymerase chain ...